Prurigo Nodularis Market Size, Share & Trend Analysis, Epidemiology and Market Forecast 2030

Prurigo Nodularis Market Size, Share & Trend Analysis, Epidemiology and Market Forecast 2030

Delveinsight Business Research
DelveInsight’s “Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis Market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Prurigo Nodularis (PN), one of the various subtypes of prurigo, is a chronic, bothersome‐to‐debilitating disease of the skin, usually seen as multiple, intensely pruritic, and excoriated nodules erupting on the surfaces of the extremities with intense itching or rubbing. PNs are cutaneous lesions often produced by repetitive scratching; hence the nickname “picker’s nodules”, which may occur as a sequel to chronic pruritus or neurotic excoriations. After establishing a perpetual itch‐scratch cycle, lichenification of the skin may ensue, resulting in chronic dermatitis termed lichen simplex chronicus. Several lesions in different stages and sizes may co‐exist in patients with chronic pruritus, which were induced by chronic scratching.

The Prurigo Nodularis market report provides in-depth current treatment practices, emerging drugs, Prurigo Nodularis market share of the individual therapies, current and forecasted Prurigo Nodularis market Size from 2017 to 2030 segmented by seven major markets. 

The report also provides comprehensive current Prurigo Nodularis Treatment practice & algorithm, market drivers, market barriers and unmet medical needs to cater best of the opportunities and assessments underlying potential of Prurigo Nodularis Market.


Prurigo Nodularis market key facts

It has been observed that most of the patients with Atopic Prurigo Nodularis account for ~75% of the total diagnosed Prurigo Nodularis cases, followed by Nonatopic Prurigo Nodularis (~25%) in the United States.  In 2017, there were around 116,653 Atopic Prurigo Nodularis and 38,884 Nonatopic Prurigo Nodularis patients in the United States. 

Among the European countries, Germany had the highest prevalent population of Prurigo Nodularis with 103,004 cases, followed by France with 57,996 cases in 2017. Spain had the lowest prevalent population with 44,273 cases in 2017.

Japan accounted for the second‐highest prevalent population of PN among the 7MM countries, with over 110,681 cases in 2017 that will increase by the end of 2028.


Request for Sample Pages:

Key benefits of Prurigo Nodularis Market report

  • Prurigo Nodularis market report provides an in-depth analysis of Prurigo Nodularis market, size, share, trend analysis, epidemiology, and market forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Prurigo Nodularis market report covers Prurigo Nodularis current treatment practices, emerging drugs, market share of the individual therapies.

  • The Prurigo Nodularis market report covers the marketed and emerging therapies of Prurigo Nodularis.

  • The Prurigo Nodularis market report helps businesses understand the Prurigo Nodularis Market trends that will shape and drive the Prurigo Nodularis market in upcoming years.

Prurigo Nodularis Market

The Prurigo Nodularis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Prurigo Nodularis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

Prurigo Nodularis Market segment gives a thorough detail of Prurigo Nodularis Market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

Prurigo Nodularis Epidemiology

The Prurigo Nodularis Epidemiology division provides insights about historical and current Prurigo Nodularis patient pool and forecasted trends for every seven major countries. 

The disease epidemiology covered in the report provides historical as well as forecasted Prurigo Nodularis Epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. 

The epidemiology segment also provides the Prurigo Nodularis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan along with diagnosed patient pools and their trends with assumptions undertaken.

The launch of the emerging therapies is expected to significantly impact the Prurigo Nodularis Treatment scenario in the upcoming years. Some of the drugs covered in the report include Serlopitant, Nalbuphine ER, KPL‐716 and others. 

The key players in the Prurigo Nodularis market include Menlo Therapeutics, Trevi Therapeutics, Kiniksa Pharmaceuticals, and many others. 


Table of content

1. Key Insights

2. Executive Summary

3. Prurigo Nodularis Competitive Intelligence Analysis

4. Prurigo Nodularis Market Overview at a Glance

5. Prurigo Nodularis Disease Background and Overview

6. Prurigo Nodularis Patient Journey

7. Prurigo Nodularis Epidemiology and Patient Population

8. Prurigo Nodularis Treatment Algorithm, Current Treatment, and Medical Practices

9. Prurigo Nodularis Unmet Needs

10. Key Endpoints of Prurigo Nodularis Treatment

11. Prurigo Nodularis Marketed Products

12. Prurigo Nodularis Emerging Therapies

13. Prurigo Nodularis Seven Major Market Analysis

14. Attribute analysis

15. Prurigo Nodularis Market Outlook (in 7 major markets)

16. Access and Reimbursement Overview of Prurigo Nodularis

17. KOL Views on the Prurigo Nodularis market.

18. Prurigo Nodularis Market Drivers

19. Prurigo Nodularis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports:-

Prurigo Nodularis Epidemiology Forecast to 2030

DelveInsight’s ‘Prurigo Nodularis Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Prurigo Nodularis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Prurigo Nodularis Pipeline Insights, 2020

“Prurigo Nodularis Pipeline Insight, 2020” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Prurigo Nodularis market. A detailed picture of the Prurigo Nodularis pipeline landscape is provided, which includes the disease overview and Prurigo Nodularis treatment guidelines.


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States